A randomised, double-blind, double-dummy, parallel-group, placebo-controlled, forced dose titration study evaluating the efficacy and safety of GW679769 and paroxetine in subjects with major depressive disorder (MDD).
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2017
At a glance
- Drugs Casopitant (Primary) ; Paroxetine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 20 May 2009 Actual patient number changed from 236 to 348 as reported by ClinicalTrials.gov.
- 29 May 2007 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History